About Sol Gel Technologies
Sol-Gel Technologies (NASDAQ:SLGL) specializes in developing and commercializing dermatological therapies. Leveraging its patented sol-gel technology, the company formulates innovative pharmaceutical products to meet the unmet needs in the treatment of skin diseases. The company's portfolio includes projects aimed at acne, rosacea, and other skin conditions, focusing on creating treatments that are more effective and safer for patients. Sol Gel Technologies is dedicated to enhancing patient care in dermatology through its research and development, aiming to bring novel solutions from the laboratory to the market. By advancing its pipeline of dermatological treatments, the company strives to address the challenges faced by individuals with skin diseases and improve their quality of life.
Snapshot
Operations
Products and/or services of Sol Gel Technologies
- TWYNEO, a drug for treating acne vulgaris, incorporating encapsulated benzoyl peroxide for enhanced efficacy.
- Epsolay, a microencapsulated benzoyl peroxide cream designed for rosacea.
- Sollas, an advanced dermatological solution aimed at treating various skin disorders through innovative encapsulation technology.
- Verido, a revolutionary product designed to combat psoriasis using proprietary drug delivery systems.
- Gelixer, a cutting-edge topical gel for alleviating symptoms of eczema, focusing on hydration and healing.
Sol Gel Technologies executive team
- Mr. Moshe ArkinCEO & Executive Chairman
- Mr. Eyal Ben-OrChief Financial Officer
- Dr. Itzik YosefChief Operating Officer
- Mr. Michael GlezinChief Business Officer